Skip to main content

Table 1 Baseline demographic and clinical characteristics of the study cohort

From: Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis

  N   
Age (years): median (Q1–Q3) 346 63 (51–72)
Disease duration (years): median (Q1–Q3) 346 10 (7–17)
BMI (kg/m2): median (Q1–Q3) 310 23.4 (21–27)
Male sex: N (%) 346 60 (17.3)
Diffuse cutaneous subset: n (%) 283 65 (23)
Raynaud’s phenomenon: n (%) 342 327 (95.6)
Digital ulcers ever: n (%) 335 114 (34.0)
mRSS: median (Q1–Q3) 337 3 (0–8)
Joint synovitis: n (%) 344 61 (17.7)
Joint contractures: n (%) 340 99 (29.1)
Esophageal symptoms (reflux, dysphagia): n (%) 344 185 (53.8)
Stomach symptoms (early satiety, vomiting): n (%) 341 102 (29.9)
Intestinal symptoms (diarrhea, bloating, constipation): n (%) 344 124 (36)
Malabsorption syndrome: n (%) 306 7 (2.3)
Intestinal pseudo-obstruction: n (%) 311 4 (1.3)
Barrett’s esophagus 343 9 (2.6)
Pulmonary hypertension: n (%) 331 35 (10.6)
Thorax HRCT: lung fibrosis: n (%) 328 135 (41.2)
FVC: median (Q1–Q3) 339 97 (84–110)
Renal crisis: n (%) 343 6 (1.7)
ANA positive: n (%) 345 340 (98.6)
Anti-centromere positive: n (%) 327 155 (47.4)
Anti-topoisomerase I positive: n (%) 332 84 (25.3)
Anti-RNA polymerase III positive: n (%) 310 36 (11.6)
CRP (mg/dl): median (Q1–Q3) 312 1.6 (0.7–4)
ESR (mm/h): median (Q1–Q3) 329 12 (6–23.5)
Hb (g/dl): median (Q1–Q3) 310 13.2 (12.4–14.1)
  1. BMI body mass index, mRSS modified Rodnan skin score, HRCT high-resolution computer tomography, FVC forced vital capacity, ANA anti-nuclear antibodies, CRP C-reactive protein, ESR erythrocyte sedimentation rate, Hb hemoglobin